Dysport
Dysport is a prescription botulinum toxin type A injection (abobotulinumtoxinA) marketed by Ipsen Biopharmaceuticals Inc. in the US, FDA-approved for cervical dystonia in adults and spasticity in patients 2 years and older, administered by trained specialists and distributed through specialty pharmacies and authorized distributors.
- Company typePrivate
- Founded2009
- HeadquartersOxford, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dysport does
Dysport is a prescription pharmaceutical product (abobotulinumtoxinA), a botulinum toxin type A injection marketed by Ipsen Biopharmaceuticals Inc., the US commercial subsidiary of France-based Ipsen Group. It is FDA-approved for treating increased muscle stiffness in patients 2 years of age and older with upper or lower limb spasticity (adult and pediatric), and for cervical dystonia in adults. The product is manufactured by Ipsen Biopharm Limited in Wrexham, UK, and distributed in the US through seven authorized specialty distributors (ASD Healthcare, Besse Medical, Cardinal Health, CuraScript SD, McKesson Specialty Health, McKesson Medical-Surgical, and Metro Medical) plus a direct ordering platform (Dysport DIRECT). The drug is administered as an intramuscular injection by trained specialists, with treatment effects lasting 12-16 weeks or longer depending on indication.
Dysport's core technology is the abobotulinumtoxinA formulation, available in 300-unit and 500-unit single-use vials with specific reconstitution and dilution protocols for each indication. The product's potency units are non-interchangeable with other botulinum toxin products (Botox, Xeomin, Myobloc), and dosing ranges vary by indication (e.g., 500-1000 Units for adult upper limb spasticity, 10-15 Units/kg for pediatric lower limb spasticity). The product has received five FDA approvals over a decade (2009-2019), progressively expanding from cervical dystonia into full adult and pediatric upper and lower limb spasticity coverage.
Dysport generates revenue through prescription drug sales via three reimbursement pathways: specialty pharmacy benefit, medical benefit buy-and-bill, and direct provider purchase. Ipsen supports commercial operations through the IPSEN CARES patient access program (copay assistance as low as $0 for eligible commercially insured patients), a nationwide Injector Locator tool, and healthcare professional education programs including injection training labs and conference presence. The brand targets neurologists, physiatrists, pediatric neurologists, and PM&R specialists, and partners with patient advocacy organizations across stroke, brain injury, dystonia, and cerebral palsy communities.
Dysport firmographics
Firmographics- Name
- Dysport
- Legal name
- Dysport (abobotulinumtoxinA)
- Website
- https://dysport.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Dysport is a prescription botulinum toxin type A injection (abobotulinumtoxinA) marketed by Ipsen Biopharmaceuticals Inc. in the US, FDA-approved for cervical dystonia in adults and spasticity in patients 2 years and older, administered by trained specialists and distributed through specialty pharmacies and authorized distributors.
- Ownership category
- akta.pro rank
Dysport industry classification
Industry- Product category
- Botulinum Toxin Therapeutics (Neurology / Specialty Pharmaceuticals)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC)
Keywords
Where Dysport is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Dysport business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Operations, Personnel
Revenue model
- Prescription Drug Sales: Dysport is sold as a prescription pharmaceutical through multiple channels: directly via Dysport DIRECT, through authorized specialty distributors (ASD Healthcare, Besse Medical, Cardinal Health, CuraScript SD, McKesson), and via specialty pharmacy benefit. Healthcare providers purchase the product and administer injections to patients, with reimbursement through medical benefit or pharmacy benefit.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Copay Assistance Program |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Dysport product offering
Product offeringCore offering
Dysport (abobotulinumtoxinA) is a prescription intramuscular injection of botulinum toxin type A, offered in 300-unit and 500-unit vials. It is FDA-approved for the treatment of cervical dystonia in adults and for upper and lower limb spasticity in adults and pediatric patients aged 2 years and older, and is administered by trained healthcare specialists such as neurologists, physiatrists, and movement-disorder physicians.
Product overview
Dysport is a single pharmaceutical product (abobotulinumtoxinA), a prescription botulinum toxin type A injection. It is FDA-approved for treating increased muscle stiffness in patients 2 years and older with spasticity (both upper and lower limb, pediatric and adult) and cervical dystonia in adults. The product is available in two vial sizes (300-Unit and 500-Unit) and is administered by trained specialists. Supporting offerings include the IPSEN CARES patient support program, Dysport Copay Assistance Program, Dysport DIRECT ordering platform, and an Injector Locator tool to help patients find trained healthcare providers.
Differentiator
Problem solved
Functional benefit
Brands
- Dysport: Botulinum toxin type A injection for treatment of spasticity and cervical dystonia
- IPSEN CARES
Products and services
- Dysport (abobotulinumtoxinA) for Injection Prescription intramuscular injection of botulinum toxin type A (abobotulinumtoxinA) indicated for the treatment of cervical dystonia in adults, supplied in 300-unit and 500-unit vials for reconstitution by trained healthcare specialists.
- Dysport (abobotulinumtoxinA) — Adult & Pediatric Spasticity Indication Botulinum toxin type A injection indicated for the treatment of upper and lower limb spasticity in adults and pediatric patients aged 2 years and older, administered intramuscularly by trained specialists.
- IPSEN CARES Patient Access Program Patient support program providing benefit verification, prior authorization assistance, financial assistance, and product ordering support for patients prescribed Dysport and other Ipsen therapies.
- Dysport DIRECT Ordering Platform Direct online ordering channel through which healthcare providers purchase Dysport units directly from Ipsen Biopharmaceuticals.
- Dysport Injector Locator Online tool that helps patients and caregivers locate trained Dysport injectors near them.
- Dysport Copay Assistance Program Financial assistance program that reduces out-of-pocket cost to $0 for eligible commercially insured patients prescribed Dysport.
Quantifiable outcome
- Approximately 3 out of 4 adults with upper limb spasticity had response to treatment at week 4 (reduction in stiffness)
- +4 more outcomes
Companies that use Dysport
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Dysport technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Dysport partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- ASD HealthcarecoreAuthorized specialty distributor for Dysport. Healthcare providers can purchase Dysport through ASD Healthcare. Phone: 1-800-746-6273.
- Besse MedicalcoreAuthorized specialty distributor for Dysport. Healthcare providers can purchase Dysport through Besse Medical. Phone: 1-800-543-2111.
- Cardinal Health Specialty PharmacycoreAuthorized specialty distributor for Dysport. Healthcare providers can purchase Dysport through Cardinal Health Specialty Pharmacy. Phone: 1-866-926-3161.
- CuraScript SDcoreAuthorized specialty distributor for Dysport. Healthcare providers can purchase Dysport through CuraScript SD. Phone: 1-877-599-7748.
- McKesson Specialty HealthcoreAuthorized specialty distributor for Dysport. Healthcare providers can purchase Dysport through McKesson Specialty Health. Phone: 1-800-482-6700.
- McKesson Medical-SurgicalcoreAuthorized specialty distributor for Dysport. Healthcare providers can purchase Dysport through McKesson Medical-Surgical. Phone: 1-800-422-0280.
- Metro MedicalcoreAuthorized specialty distributor for Dysport. Healthcare providers can purchase Dysport through Metro Medical. Phone: 1-800-768-2002.
- Alliance for Patient AccessminorPatient advocacy organization providing information and support for patients. Contact: 1-202-499-4114.
- American Stroke AssociationminorPatient advocacy organization for stroke survivors and those with spasticity. Contact: 1-888-4-STROKE.
- Brain Injury Association of AmericaminorPatient advocacy organization providing support for brain injury survivors. Contact: 1-800-444-6443.
- Dystonia Medical Research FoundationminorPatient advocacy organization for cervical dystonia. Contact: 1-800-377-3978.
- National Spasmodic Torticollis AssociationminorPatient advocacy organization for spasmodic torticollis/cervical dystonia. Contact: 1-657-554-0661.
- Spasmodic Torticollis Info CenterminorPatient advocacy organization providing information on spasmodic torticollis. Contact: 1-888-445-4588.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Dysport competitors and assessment
Company assessmentBroad incumbents
- Teva Pharmaceutical Industries: Large specialty pharma with neurology and movement disorder offerings, including in the spasticity/cervical dystonia prescribing environment. Overlaps in distribution channels and payer contracts but is not a toxin-direct competitor.
- Pfizer: Major pharma with CNS and movement disorder exposures (post Biohaven). Operates at scale in the same specialty prescriber and payer ecosystem as Dysport, though its portfolio does not include a toxin.
- Ipsen Group: Parent company and manufacturer of Dysport via Ipsen Biopharm Limited (UK); operates a broader specialty care portfolio across neurology, oncology, and rare disease. Dysport is one therapeutic franchise within Ipsen's US footprint.
- Novartis: Global pharma with neurology and rare disease franchises relevant to movement disorders and spasticity. Shares specialty distribution and provider access dynamics with Dysport without directly competing in toxins.
- H. Lundbeck: Global neurology specialty pharma with strong presence in movement disorders and adjacent conditions. Targets the same specialist physician channel (neurologists, physiatrists) as Dysport though without a botulinum toxin asset.
- Supernus Pharmaceuticals: Specialty CNS-focused pharmaceutical company with neurology and movement disorder products. Competes for the same physician and payer relationships even though its portfolio is non-toxin based.
Direct peers
- Galderma: Listed in the Dysport contact database as the 'Galderma Special Services' channel for injectables (1-800-221-1749). Operates in the aesthetics/neurology botulinum toxin space, overlapping in physician accounts and patient access programs.
- Allergan Aesthetics / AbbVie (Botox): Sells Botox (onabotulinumtoxinA), the dominant therapeutic and aesthetic botulinum toxin. Direct head-to-head competitor across all of Dysport's FDA-approved indications including cervical dystonia and adult/pediatric spasticity.
- Merz Pharmaceuticals (Xeomin): Sells Xeomin (incobotulinumtoxinA), a competing botulinum toxin type A approved for cervical dystonia, spasticity, and other indications. Same customer base (neurologists, physiatrists) with overlapping distribution and reimbursement dynamics.
- Solstice Neurosciences / US WorldMeds (Myobloc): Sells Myobloc (rimabotulinumtoxinB), a botulinum toxin type B used primarily for cervical dystonia. Competes in the same specialty neurology channel and serves overlapping prescriber specialties.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Dysport social profiles
Digital presenceDysport compliance and trust
Trust signalCompliance1 record
Dysport financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dysport leadership team
Management profileNumber of profiles
Dysport funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dysport M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dysport
What does Dysport do?
Dysport (abobotulinumtoxinA) is a prescription intramuscular injection of botulinum toxin type A, offered in 300-unit and 500-unit vials. It is FDA-approved for the treatment of cervical dystonia in adults and for upper and lower limb spasticity in adults and pediatric patients aged 2 years and older, and is administered by trained healthcare specialists such as neurologists, physiatrists, and movement-disorder physicians.
Is Dysport a public or private company?
Dysport is a private company. It is classified as corporate owned and is currently operating.
When was Dysport founded?
Dysport was founded in 2009. It employs 1 to 10 people.
Where is Dysport based?
Dysport is headquartered in Oxford, United States, in the North America region.
How does Dysport make money?
One revenue line is on record: prescription Drug Sales.
Who are Dysport's main competitors?
Broad incumbents on record are Teva Pharmaceutical Industries, Pfizer, Ipsen Group, Novartis, H. Lundbeck and Supernus Pharmaceuticals. Direct peers are Galderma, Allergan Aesthetics / AbbVie (Botox), Merz Pharmaceuticals (Xeomin) and Solstice Neurosciences / US WorldMeds (Myobloc).
Does Dysport have an API?
No public API is recorded for Dysport.
What industry is Dysport in?
Dysport's product category is Botulinum Toxin Therapeutics (Neurology / Specialty Pharmaceuticals). Its primary akta.pro industry code is HLAKAIAC, Movement Disorders (Parkinson’s, Tremor, Dystonia). Its SIC code is 2836.